Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors

L. Porcelli, A. E. Quatrale, P. Mantuano, N. Silvestris, J. F. Rolland, L. Biancolillo, A. Paradiso, A. Azzariti

Research output: Contribution to journalArticlepeer-review


Single-agent therapy with molecularly targeted agents has shown limited success in tumor growth control, mainly because escape or resistance mechanisms are activated once a signalling molecule is inhibited. Rational combinations of target-specific agents could counteract this response providing a useful strategy in cancer treatment. In this regard, the EGFR and mTOR inhibitors have been used together to generate a synergistic effect and maximize the efficacy of each individual agent. Overall, the in vivo and in vitro evidences support the utilization of combinations targeting EGFR and mTOR, for malignancies characterized by deregulated EGFR/PI3K/Akt/ mTOR signalling cascade; whereas the clinical experience points out that the assessment of the therapeutic value of such combination awaits further investigations.

Original languageEnglish
Pages (from-to)918-926
Number of pages9
JournalCurrent Pharmaceutical Design
Issue number5
Publication statusPublished - 2013


  • Biomarkers
  • Clinical trials
  • Combination therapy
  • EGFR
  • mTOR

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology


Dive into the research topics of 'Synergistic antiproliferative and antiangiogenic effects of EGFR and mTOR inhibitors'. Together they form a unique fingerprint.

Cite this